Replimune Group Inc. (REPL)
REPL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$12.11
-7.34% on the day
Market cap
$1.1B
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | REPL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001737953 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-08-14 |
| Latest annual report | 10-K | 2026-06-29 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report FORM 8-K | 8-K | 2026-09-16 |
| Latest proxy | DEFA14A | 2026-07-29 |
Source: SEC EDGAR submissions feed, 650 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.5% |
| 1 month | -11.4% |
| 3 months | +21.3% |
| Year to date | +18.8% |
| 1 year | +153.3% |
| From 52-week high | -27.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VOR | Vor Biopharma Inc. | $19.06 | -3.74% | $1.1B |
| TSHA | Taysha Gene Therapies Inc. | $3.58 | -13.53% | $1.2B |
| IMTX | Immatics N.V. | $6.83 | -5.27% | $1.0B |
| INBX | Inhibrx Biosciences Inc. | $87.08 | -3.81% | $1.3B |
| MGTX | MeiraGTx Holdings plc | $9.94 | -4.24% | $954.7M |
| COAG | Hemab Therapeutics Holdings Inc. | $29.80 | -1.94% | $1.4B |
| IMCR | Immunocore Holdings plc | $27.82 | -4.20% | $1.4B |
| CGEM | Cullinan Therapeutics Inc. | $14.10 | -5.69% | $907.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier